PSMB3

Proteasome subunit beta type-3

23,191 patent compounds predicted against PSMB3, 15,844 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL605949	0.54	15/20
SCHEMBL607010	0.56	12/20
SCHEMBL609327	0.55	12/20
SCHEMBL607553	0.54	12/20
SCHEMBL606932	0.53	12/20
SCHEMBL608381	0.53	12/20
SCHEMBL1477893	0.53	12/20
SCHEMBL609081	0.52	12/20
SCHEMBL606926	0.52	12/20
SCHEMBL606344	0.51	12/20
SCHEMBL606616	0.51	12/20
SCHEMBL1327404	0.50	12/20
SCHEMBL607035	0.61	11/20
SCHEMBL609733	0.60	11/20
SCHEMBL609324	0.60	11/20
SCHEMBL605158	0.59	11/20
SCHEMBL606315	0.59	11/20
SCHEMBL1477637	0.57	11/20
SCHEMBL609290	0.57	11/20
SCHEMBL607972	0.55	11/20

Germline variants in PSMB3 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full PSMB3 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to PSMB3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	PHASE4	UNKNOWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer	PHASE2	COMPLETED
Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas	PHASE2	COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma	PHASE2	COMPLETED
Colchicine for Amyotrophic Lateral Sclerosis	PHASE2	COMPLETED
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma	PHASE2	WITHDRAWN
Biologic Correlative Taxotere/AC	PHASE2	COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors	PHASE2	COMPLETED
3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)	PHASE2	COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma	PHASE1	COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM	PHASE1	WITHDRAWN
Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma	PHASE1	COMPLETED
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma	PHASE1	COMPLETED
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	PHASE1	COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer	PHASE1	COMPLETED
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Cardiovascular Complications of Carfilzomib Treatment	nan	UNKNOWN
Muscle Wasting in Cancer (MWIC)	nan	COMPLETED
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS)	nan	UNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
Collection of Blood Samples for DNA in Motor Neuron Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PSMB3 binder may also engage these)

Protein	Name	Similarity
P40112	—	1.000	P40112 →
P33672	—	1.000	P33672 →
O73817	—	1.000	O73817 →
Q9R1P1	—	1.000	Q9R1P1 →
Q9LST7	—	0.992	Q9LST7 →
Q9XI05	—	0.991	Q9XI05 →
O81153	—	0.987	O81153 →
O65084	—	0.970	O65084 →
Q5ZHS1	—	0.901	Q5ZHS1 →
Q17QL1	—	0.899	Q17QL1 →
Q5HZM6	—	0.898	Q5HZM6 →
Q2KHU8	—	0.897	Q2KHU8 →
Q5RIC0	—	0.897	Q5RIC0 →
Q5ZIH0	—	0.897	Q5ZIH0 →
Q9H9T3	—	0.897	Q9H9T3 →
Q641P0	—	0.896	Q641P0 →
Q8TDQ7	—	0.896	Q8TDQ7 →
Q6NVL5	—	0.896	Q6NVL5 →
Q9CQ65	—	0.896	Q9CQ65 →
P81795	—	0.895	P81795 →
C9WPN6	—	0.894	C9WPN6 →
Q9GKK5	—	0.894	Q9GKK5 →
P20461	—	0.894	P20461 →
Q3MHF7	—	0.894	Q3MHF7 →
Q2KJ61	—	0.893	Q2KJ61 →
P83888	—	0.893	P83888 →
P41091	—	0.893	P41091 →
Q9Z0N2	—	0.893	Q9Z0N2 →
A4IHW6	—	0.892	A4IHW6 →
F1QGW6	—	0.892	F1QGW6 →